» Articles » PMID: 29124205

Fluvoxamine Alleviates Paclitaxel-induced Neurotoxicity

Overview
Specialty Biochemistry
Date 2017 Nov 11
PMID 29124205
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Paclitaxel (Px) is an effective chemotherapeutic agent for the treatment of various cancers. However, it is often associated with neurological side effects, including chemotherapy-associated cognitive impairment (CACI), such as "chemobrain". Previously, we reported that endoplasmic reticulum (ER) stress is involved in Px-induced neurotoxicity, and immunoglobulin heavy chain binding protein (BiP) inducer X (BIX) alleviates Px-induced neurotoxicity. However, BIX has not been used in clinical practice yet. We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R). The purpose of this study was to investigate whether Flv could alleviate Px-induced neurotoxicity . SK-N-SH cells were pre-treated for 12 h with or without 10 μg/ml Flv followed by treatment with 1 μM Px with or without co-existence of 10 μg/ml Flv for 24 h. To investigate the involvement of Sig-1R in alleviation effect on Px-induced neurotoxicity,1 μM NE100, an antagonist of Sig-1R, was added for 24 h. Neurotoxicity was assessed using the MTS viability assay and ER stress-mediated neurotoxicity was assessed by evaluating the expression of C/EBP homologous protein (CHOP), cleaved caspase 4, and cleaved caspase 3. Pre-treatment with Flv significantly alleviated the induction of CHOP, cleaved caspase 4, and cleaved caspase 3 in SK-N-SH cells. At the same time, pre-treatment with Flv significantly induced Sig-1R in SK-N-SH cells. In addition, viability was significantly higher in Flv-treated cells than in untreated cells, which was reversed by treatment with NE100. Our results suggest that Flv alleviates Px-induced neurotoxicity in part through the induction of Sig-1R. Our findings should contribute to one of the novel approaches for the alleviation of Px-induced neurotoxicity, including chemobrain.

Citing Articles

Investigating the protective effects of fluvoxamine against sepsis-related acute lung injury through antiapoptotic, anti-inflammatory, and anti-oxidant features in rats.

Asci H, Emre Akin S, Ekrem Camas H, Bindal A, Kurtbolat O, Tasan S Iran J Basic Med Sci. 2025; 28(3):323-331.

PMID: 39906615 PMC: 11790192. DOI: 10.22038/ijbms.2024.80608.17444.


Fluvoxamine Inhibited NLRP3 and NF-κB Inflammatory Pathways and Maintained Genital Functions by Ameliorating CD-MPR, KISS-1, AQP4 and Claudin-1 Expressions.

Topsakal S, Ozmen O, Ozcan K, Asci H, Imeci O, Sevuk M Basic Clin Pharmacol Toxicol. 2025; 136(3):e70000.

PMID: 39891570 PMC: 11786297. DOI: 10.1111/bcpt.70000.


Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.

Davis M Palliat Care Soc Pract. 2024; 18:26323524241266603.

PMID: 39086469 PMC: 11289827. DOI: 10.1177/26323524241266603.


Fluvoxamine Exerts Sigma-1R to Rescue Autophagy via Pom121-Mediated Nucleocytoplasmic Transport of TFEB.

Lin C, Wu H, Weng E, Wu H, Su T, Wang S Mol Neurobiol. 2024; 61(8):5282-5294.

PMID: 38180612 PMC: 11249700. DOI: 10.1007/s12035-023-03885-9.


A narrative review of risk factors and interventions for cancer-related cognitive impairment.

Bai L, Yu E Ann Transl Med. 2021; 9(1):72.

PMID: 33553365 PMC: 7859819. DOI: 10.21037/atm-20-6443.


References
1.
Hoozemans J, van Haastert E, Eikelenboom P, de Vos R, Rozemuller J, Scheper W . Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007; 354(3):707-11. DOI: 10.1016/j.bbrc.2007.01.043. View

2.
Omi T, Tanimukai H, Kanayama D, Sakagami Y, Tagami S, Okochi M . Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor. Cell Death Dis. 2014; 5:e1332. PMC: 4123092. DOI: 10.1038/cddis.2014.301. View

3.
Narita N, Hashimoto K, Tomitaka S, Minabe Y . Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996; 307(1):117-9. DOI: 10.1016/0014-2999(96)00254-3. View

4.
Ahles T, Saykin A, Furstenberg C, Cole B, Mott L, Skalla K . Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20(2):485-93. DOI: 10.1200/JCO.2002.20.2.485. View

5.
Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J . Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol. 1999; 1(8):479-85. DOI: 10.1038/70265. View